• Joshua Slatkoff and Brian Greenfield.
• Psychiatric Out-patient Services, Peter Lougheed Centre, Room 1929, 3500--26th Avenue NE, Calgary, Alberta, T1Y 6J4, Canada. Joshua.Slatkoff@CalgaryHealthRegion.ca
• Expert Opin Investig Drugs. 2006 Jun 1;15(6):649-67.

AbstractWith increased awareness that attention-deficit/hyperactivity disorder (ADHD) can persist beyond childhood, pharmacological treatment options for adults have expanded. Short-acting stimulants continue to be the first-line approach, demonstrating clinical efficacy and few adverse events in well-controlled trials, with long-acting stimulants also showing promise. Atomoxetine has also been reported to improve ADHD symptoms and associated dysfunction, although longer-term, head-to-head studies with stimulants are needed. Several antidepressants (e.g., desipramine and buproprion) appear to be effective in the treatment of adult ADHD, but to a lesser extent than stimulants. Data are limited in evaluating the impact of combining pharmacological treatments for ADHD and comorbid conditions. This paper describes the safety and efficacy of medications for treating the core symptoms, psychosocial features and cognitive dysfunctions associated with adult ADHD.

25 keywords...

hide…